EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
EyePoint (Nasdaq: EYPT) announced that Jay S. Duker, M.D., President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT / 10:30 a.m. ET.
A live webcast and an archived replay will be available via the Investors section of the company website at www.eyepoint.bio.
Positive
- None.
Negative
- None.
News Market Reaction – EYPT
In the Dec 17 session, EYPT declined 1.59%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 19 | Phase 3 safety update | Positive | +2.3% | DSMC recommended Phase 3 DURAVYU trials continue with no safety issues. |
| Nov 17 | Inducement grants | Neutral | +13.4% | Reported stock option inducement grants to new employees under NASDAQ rules. |
| Nov 05 | Q3 2025 earnings | Negative | -11.1% | Wider loss and sharp revenue decline despite extended cash runway and trial progress. |
| Nov 03 | Investor conferences | Neutral | -4.9% | Announced multiple November investor events and webcasts for outreach. |
| Oct 29 | Earnings date notice | Neutral | -4.2% | Set reporting date and call details for Q3 2025 financial results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Stock often reacts in line with the tone of substantive clinical or financing news, while routine scheduling announcements have sometimes seen mild negative divergence.
Over the last few months, EyePoint advanced pivotal Phase 3 programs for DURAVYU in wet AMD and DME, completed enrollment of >900 patients, and reported Q3 2025 results with an extended cash runway into Q4 2027. The company also executed significant equity financings and launched an ATM program. Prior conference-participation announcements in November 2025 drew modestly negative reactions, so this new J.P. Morgan conference appearance continues a pattern of active investor outreach alongside late-stage development progress.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT/10:30 a.m. ET.
A webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepoint.bio.
About EyePoint
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration with expected topline data beginning in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema is expected in the first quarter of 2026.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Tanner.Kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
